FOXO4-DRI
Lab-Tested ≥98% Purity · Certificate of Analysis Included · Global Shipping
FOXO4-DRI — Senolytic Peptide for Cellular Aging Research
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 transcription factors in senescent cells. First described by Baar et al. (2017) in Cell, this peptide selectively induces apoptosis in senescent cells by preventing FOXO4-mediated nuclear exclusion of p53, thereby restoring the cell's ability to undergo programmed cell death. As a targeted senolytic agent, FOXO4-DRI has become a pivotal research tool in the study of cellular senescence and age-related tissue dysfunction.
Mechanism of Action
FOXO4-DRI is engineered as a D-amino acid retro-inverso peptide, conferring exceptional proteolytic stability compared to native L-peptide sequences. In senescent cells, FOXO4 sequesters p53 in the nucleus through direct protein-protein interaction, preventing apoptotic signaling. FOXO4-DRI competitively binds FOXO4, disrupting this complex and allowing p53 to translocate to mitochondria, where it triggers caspase-dependent apoptosis. Crucially, this mechanism is selective for senescent cells—non-senescent cells with low FOXO4 expression remain unaffected.
Key Research Areas
- Cellular Senescence: Landmark research demonstrated that FOXO4-DRI selectively eliminates senescent cells in aged murine models, resulting in restoration of fur density, renal function, and physical performance parameters including running wheel activity.
- Senescence-Associated Secretory Phenotype (SASP): By clearing senescent cells, FOXO4-DRI reduces the pro-inflammatory SASP milieu, which has been implicated in chronic tissue inflammation and age-related pathology progression.
- Chemotherapy-Induced Senescence: Preclinical models have demonstrated that FOXO4-DRI can mitigate doxorubicin-induced cellular senescence, a significant contributor to chemotherapy side effects and long-term tissue damage.
- Tissue Regeneration: Researchers have observed enhanced tissue repair capacity following senescent cell clearance, particularly in hepatic, renal, and dermal tissue models.
Technical Specifications
- Dosage per vial: 5mg lyophilized powder
- Purity: ≥98% (HPLC verified)
- Peptide Type: D-retro-inverso modified peptide
- Storage: -20°C, protected from light
Why Researchers Choose Peptides BioLab
Every batch of FOXO4-DRI supplied by Peptides BioLab undergoes rigorous HPLC and mass spectrometry analysis, ensuring ≥98% purity verified by an independent Certificate of Analysis (CoA). Our FOXO4-DRI is supplied as a lyophilized powder for maximum stability and shelf life, shipped worldwide from our state-of-the-art facilities in temperature-controlled packaging.
Related Research Peptides
Researchers studying senescence and aging pathways may also find these compounds relevant: Epitalon, GHK-Cu, and Pinealon. For a complete overview, browse our Anti-Aging Research collection.
For research purposes only — Not for human consumption. All products are intended solely for in-vitro research and laboratory use.
Every Peptides BioLab product includes a Certificate of Analysis (CoA) with HPLC and MS data confirming ≥98% purity. The CoA is available in the product tabs as the 2nd image, or contact our team to request a copy.
Shipping: We ship worldwide from our state-of-the-art facilities. Orders are processed within 1–2 business days. Express and standard shipping options available at checkout.
Storage: Store lyophilized peptides at -20°C for long-term storage. Once reconstituted, store at 2–8°C and use within 30 days. Keep away from direct sunlight.
